Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence

In recent years, the options in treatment of diabetes mellitus type 2 have substantially expanded (currently more than 40 molecules are approved), however, the number of patients with decompensation of diabetes for the period from 2003 to 2014 remains unchanged. In clinical guidelines injecting drug...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Olesya Y. Gurova, Valentin V. Fadeev, Ekaterina S. Maloletkina
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	diabetes mellitus type 2 adherence injectable treatment Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/9a28a6f67134498a832357c1716dc26a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a28a6f67134498a832357c1716dc26a
record_format	dspace
spelling	oai:doaj.org-article:9a28a6f67134498a832357c1716dc26a2021-11-14T09:00:22ZInjectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence2072-03512072-037810.14341/DM9603https://doaj.org/article/9a28a6f67134498a832357c1716dc26a2018-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9603https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378In recent years, the options in treatment of diabetes mellitus type 2 have substantially expanded (currently more than 40 molecules are approved), however, the number of patients with decompensation of diabetes for the period from 2003 to 2014 remains unchanged. In clinical guidelines injecting drugs are given the «final» role as the most effective drugs. However in clinical trials injecting drugs showed a lower adherence compared to oral drugs. Currently injectable glucose lowering drugs include not only insulin but also analogues of glucagon-like peptide-1 (aGLP-1). However, majority of studies of treatment compliance in type 2 diabetes mellitus considered only insulin. Reasons of low compliance are: 1) offering comprehensive programmes for education, monitoring and patient support by primary care physicians; 2) addressing cost and availability issues; 3) prescribing current insulin, also in combination with GLP-1 agonists; 4) use of more simple and convenient devices for injecting insulin.Olesya Y. GurovaValentin V. FadeevEkaterina S. MaloletkinaEndocrinology Research Centrearticlediabetes mellitus type 2adherenceinjectable treatmentNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 6, Pp 524-533 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus type 2 adherence injectable treatment Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus type 2 adherence injectable treatment Nutritional diseases. Deficiency diseases RC620-627 Olesya Y. Gurova Valentin V. Fadeev Ekaterina S. Maloletkina Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
description	In recent years, the options in treatment of diabetes mellitus type 2 have substantially expanded (currently more than 40 molecules are approved), however, the number of patients with decompensation of diabetes for the period from 2003 to 2014 remains unchanged. In clinical guidelines injecting drugs are given the «final» role as the most effective drugs. However in clinical trials injecting drugs showed a lower adherence compared to oral drugs. Currently injectable glucose lowering drugs include not only insulin but also analogues of glucagon-like peptide-1 (aGLP-1). However, majority of studies of treatment compliance in type 2 diabetes mellitus considered only insulin. Reasons of low compliance are: 1) offering comprehensive programmes for education, monitoring and patient support by primary care physicians; 2) addressing cost and availability issues; 3) prescribing current insulin, also in combination with GLP-1 agonists; 4) use of more simple and convenient devices for injecting insulin.
format	article
author	Olesya Y. Gurova Valentin V. Fadeev Ekaterina S. Maloletkina
author_facet	Olesya Y. Gurova Valentin V. Fadeev Ekaterina S. Maloletkina
author_sort	Olesya Y. Gurova
title	Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
title_short	Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
title_full	Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
title_fullStr	Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
title_full_unstemmed	Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
title_sort	injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/9a28a6f67134498a832357c1716dc26a
work_keys_str_mv	AT olesyaygurova injectabletherapyintype2diabetesmellitusstrategiestoimprovetherapeuticadherence AT valentinvfadeev injectabletherapyintype2diabetesmellitusstrategiestoimprovetherapeuticadherence AT ekaterinasmaloletkina injectabletherapyintype2diabetesmellitusstrategiestoimprovetherapeuticadherence
_version_	1718429478667943936

Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence

Ejemplares similares